2-(methoxymethyloxy)-4,6-dimethylbenzaldehyde | 119900-44-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(methoxymethyloxy)-4,6-dimethylbenzaldehyde
• 英文别名: 2-methoxymethoxy-4,6-dimethylbenzaldehyde；2-(Methoxymethoxy)-4,6-dimethylbenzaldehyde
• CAS: 119900-44-6
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: UCJIRCOIDRPMLL-UHFFFAOYSA-N

物化性质

• 沸点：
  321.5±42.0 °C(Predicted)
• 密度：
  1.075±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(methoxymethyloxy)-4,6-dimethylbenzaldehyde 在 10% palladium on activated carbon 4-二甲氨基吡啶 、 氢气 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 39.33h， 生成 2-[4-(3-benzoyloxypropyl)benzyl]-3,5-dimethylphenol
  参考文献：
  名称：

  GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1367060B1
• 作为产物：
  描述：

  2-羟基-4,6-二甲基苯甲醛 、 氯甲基甲基醚 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 23.0h， 以81%的产率得到2-(methoxymethyloxy)-4,6-dimethylbenzaldehyde
  参考文献：
  名称：

  半胱氨酸蛋白酶模型肽的紫外线响应捕获和释放系统的开发

  摘要：

  由于半胱氨酸蛋白酶参与多种疾病，因此它们是有吸引力的药物靶标。为了评估特定蛋白酶作为药物靶标的潜力，使用控制蛋白酶活性的试剂是必不可少的。在这种情况下，我们开发了一种捕获释放试剂，该试剂首先与半胱氨酸蛋白酶的活性中心硫醇形成共价键以抑制其活性，然后通过紫外线照射将其除去，从而释放出母体活性蛋白酶。在本文中，描述了硫醇捕获和释放试剂的设计和合成。还报道了其在源自caspase-9活性位点的模型肽的笼罩（捕获）和UV诱导的解笼（释放）中的应用以及在试剂上引入识别部分的报道。

  DOI：

  10.1016/j.tet.2011.09.062

文献信息

• Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
  申请人：Fujikura Hideki

  公开号：US20050113315A1

  公开（公告）日：2005-05-26

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R 1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted(lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及一种由通式表示的葡萄糖吡喃氧基苯基苯乙烯衍生物： 其中，R1表示氢原子，羟基，取代或未取代的氨基，氨基甲酰基，取代或未取代的（较低烷基）基团，取代或未取代的（较低烷氧基）基团等；R2表示氢原子或较低烷基基团；R3表示取代或未取代的（较低烷基）基团，取代或未取代的（较低烷氧基）基团，取代或未取代的（较低烷硫基）基团等，或其药学上可接受的盐，其具有对人类SGLT2的抑制活性，可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，以及包含它们的制药组合物和中间体。
• Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
  申请人：——

  公开号：US20040138148A1

  公开（公告）日：2004-07-15

  The present invention provides glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein P represents a hydrogen atom or a group forming a prodrug; R 1 represents a hydrogen atom, an optionally substituted amino group, a carbamoyl group, an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkylthio group, etc., which have an improved oral absorption, and exert an inhibitory activity in human SGLT2, and therefore are useful as drugs for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications or obesity, or pharmaceutically acceptable salts thereof, and pharmaceutical uses thereof.

  本发明提供了由下式表示的葡萄糖吡喃基氧基苄基苯衍生物：1其中P代表氢原子或形成前药的基团；R1代表氢原子、可选取代氨基、氨基甲酰基、可选取代的低碳基、可选取代的低碳氧基等；R2代表氢原子或低碳基；R3代表可选取代的低碳基、可选取代的低碳氧基、可选取代的低碳硫基等。这些衍生物具有良好的口服吸收性，并在人类SGLT2中表现出抑制活性，因此可用于预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症，或其药学上可接受的盐和药用用途。
• Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
  申请人：——

  公开号：US20040063170A1

  公开（公告）日：2004-04-01

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein R 1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted (lower alkyl) group, a substituted or unsubstituted (lower alkoxy) group etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents a substituted or unsubstituted (lower alkyl) group, a substituted or unsubstituted (lower alkoxy) group, a substituted or unsubstituted (lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及由下式表示的葡萄糖吡喃基氧基苯基苯基衍生物： 其中，R1代表氢原子、羟基、取代或未取代的氨基、氨基甲酰基、取代或未取代的(较低烷基)基团、取代或未取代的(较低烷氧基)基团等；R2代表氢原子或较低烷基基团；R3代表取代或未取代的(较低烷基)基团、取代或未取代的(较低烷氧基)基团、取代或未取代的(较低烷硫基)基团等，或其药学上可接受的盐，其在人类SGLT2中具有抑制活性，并且可用作预防或治疗与高血糖有关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂。本发明还涉及包含上述衍生物的制药组合物及其中间体。
• TRISUBSTITUTED BORON-CONTAINING MOLECULES
  申请人：Xia Yi

  公开号：US20110136763A1

  公开（公告）日：2011-06-09

  This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections.

  这项发明主要涉及3,4,6-三取代苯并硼酸酯化合物及其用于治疗细菌感染的用途。
• GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1344780A1

  公开（公告）日：2003-09-17

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted (lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及通式代表的葡糖基吡喃氧基苄基苯衍生物： 其中R1代表氢原子、羟基、取代或未取代的氨基、氨基甲酰基、取代或未取代的(低级烷基)基团、取代或未取代的(低级烷氧基)基团等；R2代表氢原子或低级烷基；R3代表取代或未取代的(低级烷基)基团、取代或未取代的(低级烷氧基)基团、取代或未取代的(低级烷硫基)基团等、或其药学上可接受的盐，它们对人类 SGLT2 具有抑制活性，可用作预防或治疗与高血糖有关的疾病（如糖尿病、糖尿病并发症或肥胖症）的制剂、包含这些制剂的药物组合物及其中间体。